Pfizer requests EUA for oral COVID-19 antiviral treatment
Pfizer today announced its formal request that the Food and Drug Administration authorize the emergency use of its PAXLOVID (PF-07321332; ritonavir) oral antiviral for combating SARS-CoV-2. Pfizer says data from its phase 2/3 clinical trial shows that the drug, which works as a 3CL protease inhibitor, reduced the risk of COVID-19-related hospitalization or death by 89%.
Related News Articles
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…